epvantageJune 13, 2017
Tag:
Three proved to be the charm for Lexicon Pharmaceuticals after it reported its third set of positive phase III data for its novel SGLT1/2 drug sotagliflozin in type 1 diabetes.
The results reported at the American Diabetes Association conference not only keep it and partner Sanofi on track for a first-quarter filing next year, but the continued efficacy and safety data could lend support for the two groups’ further efforts in the crowded type 2 diabetes field.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: